Synairgen (GB:SNG) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Synairgen plc has announced the retirement of Chairman Simon Shaw and the appointment of Mark Parry-Billings as his successor after the upcoming AGM on October 10, 2024. Parry-Billings brings over 30 years of experience in biotech and pharmaceuticals, notably in respiratory therapeutics, to Synairgen, a company focused on developing SNG001, an inhaled antiviral treatment for severe viral lung infections.
For further insights into GB:SNG stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
- Ford Mustang Cobra Jet Fastest Electric Car on the Planet, Ford Stock (NYSE:F) Notches Up
- “…Overlook a Lack of Earnings Power”: UBS Analysts Target Intel Stock (NASDAQ:INTC), Stock Gains
- “…Significantly Extend the Reach and Lethality of our Fleet”: Boeing Stock (NYSE:BA) Slips Despite Successful MQ-25A Test